The dopamine D(3) receptor antagonist YQA14 that inhibits the expression and drug-prime reactivation of morphine-induced conditioned place preference in rats.
Increasing evidence suggests that the mesolimbic dopamine system plays a critical role in opioid addiction. However, there is currently no standard drug treatment for opioid addiction. Growing preclinical evidence indicates that the dopamine D(3) receptor antagonists are the potential anti-addiction pharmacotherapeutic agents based on animal models of multiple drug addiction. In this study, we investigated the inhibitory effects of YQA14, a novel dopamine D(3) receptor antagonist with a high affinity and selectivity for dopamine D(3) receptor, using morphine-induced conditioned place preference (CPP) in rats. The results suggested that YQA14 (6.25-25 mg/kg; intraperitoneal, i.p.) decreased the expression of morphine (10 mg/kg, s.c.)-induced CPP in a dose-related manner but did not influence the acquisition of morphine-induced CPP. At a 25 mg/kg dose of YQA14, it also notably inhibited the reactivation of morphine-priming CPP. These findings suggest that YQA14 is a potential agent for anti-opioid addiction which warrants further study and development.
Rongrong
R
Hu
Rui
R
Song
Rifang
R
Yang
Ruibin
R
Su
Jin
J
Li
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001583:Benzoxazoles / Q000494:pharmacology*; D003213:Conditioning, Psychological / Q000187:drug effects*; D018492:Dopamine Antagonists / Q000494:pharmacology*; D005108:Extinction, Psychological; D008297:Male; D009021:Morphine Dependence / Q000523:psychology*; D010879:Piperazines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D050637:Receptors, Dopamine D3 / Q000037:antagonists & inhibitors*
D001583:Benzoxazoles; D018492:Dopamine Antagonists; D010879:Piperazines; D050637:Receptors, Dopamine D3; C571881:YQA14